
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Medicus Pharma Ltd. Warrant (MDCXW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MDCXW (3-star) is a REGULAR-BUY. BUY since 66 days. Profits (110.08%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit 94.86% | Avg. Invested days 40 | Today’s Advisory Regular Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.35 - 4.10 | Updated Date 06/28/2025 |
52 Weeks Range 0.35 - 4.10 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Medicus Pharma Ltd. Warrant
Company Overview
History and Background
Medicus Pharma Ltd. Warrant's history and background are not publicly available. Warrant details are tied to Medicus Pharma, Inc., a now defunct company. This analysis will focus on information generally applicable to warrants as a financial instrument.
Core Business Areas
- Warrant Trading: Warrants are derivative securities that give the holder the right, but not the obligation, to buy company stock at a specific price before a certain date. Warrant holders can buy or sell the warrants themselves.
Leadership and Structure
Warrants do not have their own leadership or organizational structure; their value is derived from the underlying company. In this case the warrant related to Medicus Pharma, Inc. which is no longer in existence.
Top Products and Market Share
Key Offerings
- Warrant Trading: The offering here is the *right* to purchase the underlying stock. Market share is not applicable in the conventional sense for a warrant, because it does not represent a business segment with competitors, but rather a financial mechanism that may have many different underlying assets to which it is applicable. The value will be based on the price and time left until expiration. Competitors are other securities that are applicable to the underlying stock.
Market Dynamics
Industry Overview
The warrant market is a subset of the broader derivatives market. It allows investors to gain leveraged exposure to underlying assets.
Positioning
The warrant's position is directly tied to the underlying stock (Medicus Pharma, Inc.). However, given Medicus Pharma, Inc.'s status, this warrant likely has minimal to no value. Warrants provide leveraged exposure but also carry higher risk.
Total Addressable Market (TAM)
The TAM for warrants is immense, covering all tradable derivatives. The specific warrant for Medicus Pharma would have been linked to Medicus Pharma's market capitalization and future expectations which given the company being defunct would likely result in a zero total market value.
Upturn SWOT Analysis
Strengths
- Potential for high leverage
- Relatively low cost compared to the underlying stock (when active)
Weaknesses
- High risk of loss
- Time decay (value decreases as expiration approaches)
- Often illiquid
Opportunities
- Potential for high returns with minimal capital outlay (when the underlying stock performs well)
- Hedging tool
Threats
- Expiration worthless if the stock price doesn't reach the strike price
- Market volatility impacting underlying stock
- Company-specific risks affecting the underlying stock, such as going defunct
Competitors and Market Share
Key Competitors
Competitive Landscape
Not applicable as there are no specific competitors for a warrant other than instruments on the underlying asset
Growth Trajectory and Initiatives
Historical Growth: Warrant's value tracked the growth of the underlying stock, Medicus Pharma, Inc.
Future Projections: Given that Medicus Pharma is defunct, there are no positive future projections.
Recent Initiatives: Not applicable; Medicus Pharma no longer exists.
Summary
Medicus Pharma Ltd. Warrant represents the right to purchase stock in Medicus Pharma, Inc. Given the fact that Medicus Pharma, Inc. is defunct, it is highly unlikely this warrant will have any value. This warrant's value is derived solely from the underlying company's stock performance. Due to the nature of Medicus Pharma's current status, investors holding this warrant are likely to experience significant or total loss.
Peer Comparison
Sources and Disclaimers
Data Sources:
- General knowledge of warrants and derivative markets
- Information regarding Medicus Pharma, Inc.'s status.
Disclaimers:
This analysis is based on the assumption that Medicus Pharma Ltd. Warrant is directly tied to the now-defunct Medicus Pharma, Inc. Investing in warrants involves substantial risk and should only be considered by sophisticated investors who understand the risks involved. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Medicus Pharma Ltd. Warrant
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-11-14 | CEO & Executive Chairman Dr. Raza Bokhari M.B.A., M.D., MBA | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees - | Website https://medicuspharma.com |
Full time employees - | Website https://medicuspharma.com |
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets. It develops SkinJect for the treatment of basal cell carcinoma. The company was founded in 2015 and is headquartered in Toronto, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.